Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Neuroscience and Biobehavioral Reviews

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.neubiorev.2009.05.006PMID 19481107PMCID PMC2706927
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

  2009cited by this paper
• Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis.

  2009cited by this paper
• Lacunar stroke is associated with diffuse blood–brain barrier dysfunction

  2009cited by this paper
• Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration.

  2009cited by this paper
• Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia

  2009cited by this paper
• Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

  2008influential reference
• A Generic Mechanism of Emergence of Amyloid Protofilaments from Disordered Oligomeric Aggregates

  2008cited by this paper
• Gamma-secretase inhibition and modulation for Alzheimer's disease.

  2008influential reference
• Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

  2008cited by this paper
• Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging : A possible role in progressive neurodegeneration

  2008cited by this paper
• One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures

  2008cited by this paper
• Involvement of cholesterol in the pathogenesis of Alzheimer's disease: role of statins.

  2008cited by this paper
• P4‐292: Regional variations in age dependence of P‐gp‐mediated transport across the blood‐brain barrier measured using (R)‐[11C]verapamil and PET

  2008cited by this paper
• Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

  2008cited by this paper
• O3‐04–05: Clinical trials of bapineuzumab, a beta‐amyloid‐targeted immunotherapy in patients with mild to moderate Alzheimer's disease

  2008cited by this paper
• d‐Amino acids in the brain: d‐serine in neurotransmission and neurodegeneration

  2008cited by this paper
• 2008 Alzheimer's disease facts and figures

  2008cited by this paper
• Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.

  2008cited by this paper
• ABC multidrug transporters: structure, function and role in chemoresistance.

  2008cited by this paper
• Amyloid-β Peptide (Aβ) Neurotoxicity Is Modulated by the Rate of Peptide Aggregation: Aβ Dimers and Trimers Correlate with Neurotoxicity

  2008cited by this paper
• Self-templated nucleation in peptide and protein aggregation.

  2008cited by this paper
• Apolipoprotein E, Amyloid-&bgr;, and Blood-Brain Barrier Permeability in Alzheimer Disease

  2008cited by this paper
• Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

  2008cited by this paper
• Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function.

  2008influential reference
• β-Secretase as a therapeutic target for Alzheimer’s disease

  2008cited by this paper
• Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.

  2008influential reference
• Simulating oligomerization at experimental concentrations and long timescales: A Markov state model approach.

  2008cited by this paper
• Presenilin: running with scissors in the membrane.

  2007cited by this paper
• Mechanisms of drug resistance in status epilepticus

  2007cited by this paper
• Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models*

  2007cited by this paper
• A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity

  2007cited by this paper
• Role of ABCG1 and ABCA1 in Regulation of Neuronal Cholesterol Efflux to Apolipoprotein E Discs and Suppression of Amyloid-β Peptide Generation*

  2007cited by this paper
• ABCA2 Deficiency Results in Abnormal Sphingolipid Metabolism in Mouse Brain*

  2007cited by this paper
• Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol.

  2007cited by this paper
• MDR1‐P‐Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s Amyloid‐β Peptides—Implications for the Mechanisms of Aβ Clearance at the Blood–Brain Barrier

  2007cited by this paper
• Drug Transporters in the Epileptic Brain

  2007cited by this paper
• Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models.

  2007cited by this paper
• Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

  2006cited by this paper
• Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice

  2006cited by this paper
• Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma

  2006cited by this paper
• Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier.

  2006cited by this paper
• Multidrug Resistance-Associated Proteins: Expression and Function in the Central Nervous System

  2006cited by this paper
• Distinct Early Folding and Aggregation Properties of Alzheimer Amyloid-β Peptides Aβ40 and Aβ42

  2006cited by this paper
• ABC transporters, neural stem cells and neurogenesis – a different perspective

  2006cited by this paper
• Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42.

  2006cited by this paper
• Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease

  2006cited by this paper
• DISTINCT EARLY FOLDING AND AGGREGATION PROPERTIES OF ALZHEIMER AMYLOID-ß PEPTIDE Aß40 AND Aß42: STABLE TRIMER OR TETRAMER FORMATION BY Aß42.

  2006cited by this paper
• A specific amyloid-beta protein assembly in the brain impairs memory.

  2006influential reference
• A specific amyloid-β protein assembly in the brain impairs memory

  2006influential reference
• Regional variations in age dependence of P-gp-mediated transport across the blood–brain barrier measured using (R)-[11C]verapamil and PET

  2006cited by this paper
• [Epidemiology of Alzheimer disease and related disorders].

  2006cited by this paper
• Astrocyte–endothelial interactions at the blood–brain barrier

  2006cited by this paper
• Épidémiologie de la maladie d’Alzheimer et des syndromes apparentés

  2006cited by this paper
• Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology

  2006cited by this paper
• Immunohistochemical Localization of P-glycoprotein in Rat Brain and Detection of Its Increased Expression by Seizures Are Sensitive to Fixation and Staining Variables

  2005cited by this paper
• Drug resistance in brain diseases and the role of drug efflux transporters

  2005influential reference
• P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.

  2005cited by this paper
• Characterization of ABC transporter ABCB1 expressed in human neural stem/progenitor cells

  2005cited by this paper
• Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

  2005cited by this paper
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005cited by this paper
• Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.

  2005cited by this paper
• Functional expression of ABCG2 transporter in human neural stem/progenitor cells.

  2005cited by this paper
• Blood–brain barrier dysfunction in parkinsonian midbrain in vivo

  2005influential reference
• Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

  2004cited by this paper
• Modulation of Cellular Cholesterol Alters P-Glycoprotein Activity in Multidrug-Resistant Cells

  2004cited by this paper
• Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

  2004cited by this paper
• Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy

  2004cited by this paper
• Wnt Signaling Mutants Have Decreased Dentate Granule Cell Production and Radial Glial Scaffolding Abnormalities

  2004cited by this paper
• Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition.

  2004cited by this paper
• Functional Expression and Localization of P-glycoprotein in the Central Nervous System: Relevance to the Pathogenesis and Treatment of Neurological Disorders

  2004cited by this paper
• The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• ABC transporters and the blood-brain barrier.

  2004cited by this paper
• Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures.

  2004cited by this paper
• Clearing amyloid through the blood–brain barrier

  2004cited by this paper
• Genetic polymorphisms of the human MDR1 drug transporter.

  2003cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• Drug efflux transporters in the CNS.

  2003cited by this paper
• Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

  2003cited by this paper
• Genetic background regulates β-amyloid precursor protein processing and β-amyloid deposition in the mouse

  2003cited by this paper
• Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

  2003cited by this paper
• Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele.

  2003cited by this paper
• P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain.

  2003cited by this paper
• Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

  2003cited by this paper
• Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse.

  2003cited by this paper
• Subcellular localization and activity of multidrug resistance proteins.

  2003cited by this paper
• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

  2003cited by this paper
• Structural and functional aspects of the blood-brain barrier.

  2003cited by this paper
• The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria

  2002cited by this paper
• Cerebral β-amyloid deposition is augmented by the –491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E ε4 allele

  2002cited by this paper
• Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans.

  2002cited by this paper
• Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

  2002cited by this paper
• Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4

  2002cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• Blood-brain barrier, brain metabolism and cerebral blood flow.

  2002cited by this paper
• Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis

  2002cited by this paper
• Functional expression and localization of P‐glycoprotein at the blood brain barrier

  2002cited by this paper
• Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease

  2002cited by this paper
• Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

  2002cited by this paper

• Design of a Multi‐Epitope Vaccine Targeting α‐Synuclein for Parkinson's Disease Using Immunoinformatics Tools

  2025cites this paper
• Nanotherapeutic smart approaches for combating Alzheimer’s disease and overcoming existing obstacles: A novel eco-friendly green approach

  2025cites this paper
• Apolar Extracts of St. John’s Wort Alleviate the Effects of β-Amyloid Toxicity in Early Alzheimer’s Disease

  2024cites this paper
• Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease

  2023cites this paper
• Transcriptomic and glycomic analyses highlight pathway-specific glycosylation alterations unique to Alzheimer’s disease

  2023cites this paper
• Systems Biology Approach of Understanding Insulin Resistance: Linkage between Type 2 Diabetes & Alzheimer’s Disease

  2022cites this paper
• A Novel Huntington’s Disease Assessment Platform to Support Future Drug Discovery and Development

  2022cites this paper
• Physicochemistry shapes bioactivity landscape of pan-ABC transporter modulators: Anchor point for innovative Alzheimer's disease therapeutics.

  2022cites this paper
• The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease

  2022cites this paper
• Emerging two-dimensional materials-enabled diagnosis and treatments of Alzheimer's disease: Status and future challenges

  2021cites this paper
• Role of ABCA7 in Human Health and in Alzheimer’s Disease

  2021cites this paper
• Strategies to gain novel Alzheimer’s disease diagnostics and therapeutics using modulators of ABCA transporters

  2021cites this paper
• Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer's pathology: Insights and therapeutic approaches from periphery.

  2021influential citation
• Dimethyl fumarate does not mitigate cognitive decline and β-amyloidosis in female APPPS1 mice.

  2021cites this paper
• Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain

  2021influential citation
• Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

  2020cites this paper
• Alteration in the Function and Expression of SLC and ABC Transporters in the Neurovascular Unit in Alzheimer’s Disease and the Clinical Significance

  2020cites this paper
• Vesicular ATP-binding cassette transporters in human disease: relevant aspects of their organization for future drug development

  2020cites this paper
• Using a qPCR device to screen for modulators of ABC transporter activity: A step-by-step protocol.

  2020cites this paper
• Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review.

  2019cites this paper
• Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease.

  2019cites this paper
• Preparation of Benzothiazolyl-Decorated Nanoliposomes

  2019cites this paper
• Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease.

  2019cites this paper
• Peptides as Potential Therapeutics for Alzheimer’s Disease

  2018cites this paper
• Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET

  2018cites this paper
• An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40.

  2018cites this paper
• Physicochemical Properties for Potential Alzheimer’s Disease Drugs

  2017cites this paper
• Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials

  2017cites this paper
• Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice.

  2017cites this paper
• The choroid plexus in health and in disease: dialogues into and out of the brain.

  2017cites this paper
• Endothelial LRP1 – A Potential Target for the Treatment of Alzheimer’s Disease

  2017cites this paper
• Arzneipflanzen – nur Placebos oder doch potente, den Chemotherapeutika vergleichbare Arzneimittel?

  2016cites this paper
• The Rationale for Insulin Therapy in Alzheimer’s Disease

  2016cites this paper
• Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.

  2016cites this paper
• Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease

  2016cites this paper
• Importance of ABC Transporters in Drug Development.

  2016cites this paper
• Potential use of nanomedicines for drug delivery across the BBB in health and diseased brain.

  2016cites this paper
• Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes

  2016cites this paper
• Accumulation of murine amyloid-β mimics early Alzheimer's disease.

  2015cites this paper
• Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease.

  2015cites this paper
• Autophagy in Alzheimer’s disease: A Cleaning Service Out-of-order?

  2015cites this paper
• Blood-brain barrier impairment in dementia: current and future in vivo assessments.

  2015cites this paper
• Nanoliposomes presenting on surface a cis-glycofused benzopyran compound display binding affinity and aggregation inhibition ability towards Amyloid β1-42 peptide.

  2014cites this paper
• Nanotechnology and Alzheimer's disease: what has been done and what to do.

  2014cites this paper
• Literature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease

  2014cites this paper
• Alzheimer's and ABC transporters--new opportunities for diagnostics and treatment.

  2014cites this paper
• Cerebral ABC transporter-common mechanisms may modulate neurodegenerative diseases and depression in elderly subjects.

  2014cites this paper
• Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.

  2014cites this paper
• Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary.

  2014cites this paper
• Genomic background-related activation of microglia and reduced β-amyloidosis in a mouse model of Alzheimer's disease.

  2013cites this paper
• Amyloid-β peptides, Alzheimer's disease and the blood-brain barrier.

  2013cites this paper
• Impaired mitochondrial energy production and ABC transporter function-A crucial interconnection in dementing proteopathies of the brain.

  2013cites this paper
• Insulin resistance: an emerging link in Alzheimer’s disease

  2013cites this paper
• Proteases in the Nervous System

  2013cites this paper
• Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.

  2013cites this paper
• Embedding Aβ42 in heterogeneous membranes depends on cholesterol asymmetries.

  2013cites this paper
• Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.

  2013cites this paper
• Amyloid-β Interacts with Blood-Brain Barrier Function in Dementia: A Systematic Review

  2013cites this paper
• Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

  2013cites this paper
• Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation.

  2012cites this paper
• ABC Transporters B1, C1 and G2 Differentially Regulate Neuroregeneration in Mice

  2012cites this paper
• Novel Use of Dual Anti-Inflammatory Therapy to Overcome Drug Resistance and Improve Functional Recovery Following Spinal Cord Injury

  2012cites this paper
• Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice.

  2011cites this paper
• Automated Detection of Amyloid-β-Related Cortical and Subcortical Signal Changes in a Transgenic Model of Alzheimer's Disease using High-Field MRI

  2011cites this paper
• LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier.

  2011cites this paper
• Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression.

  2011cites this paper
• Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer's disease.

  2011cites this paper
• Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide.

  2011cites this paper
• Transport of drugs across the blood-brain barrier in Alzheimer's disease.

  2010cites this paper
• Structure and properties of drug-loaded polymeric nanoparticles targeting β-amyloid

  2010cites this paper
• Amyloid and Alzheimer’s disease

  2010cites this paper
• Antiviral agents in Alzheimer’s disease: hope for the future?

  2010cites this paper
• Direct observation of nucleation and growth in amyloid self-assembly.

  2010cites this paper
• Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid-β clearance in Alzheimer's disease.

  2010cites this paper